Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Activated bifidobacteria and methods of use thereof

A bifidobacterium, composition technology, applied in the direction of bifidobacteria, application, bacteria used in food preparation, etc., can solve the problems of lack of beneficial bifidobacteria ecology, imbalance, etc.

Inactive Publication Date: 2017-10-13
EVOLVE BIOSYST
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, dysbiosis may also be caused by the absence of beneficial bifidobacteria in infants due to disease or medical intervention (e.g., antibiotic therapy)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activated bifidobacteria and methods of use thereof
  • Activated bifidobacteria and methods of use thereof
  • Activated bifidobacteria and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1. Preparation of a certain bifidobacterium-specific human milk oligosaccharide (HMO) composition

[0066] A concentrated mixture of HMOs was obtained by a method similar to that described by Fournell et al. (US Patent Application 20150140175). Human milk is pasteurized and centrifuged to separate it into milkfat (mainly fat) and skim milk (skimmed product). The skim milk is then ultrafiltered using a membrane with a 5-10 kDa cut-off to concentrate the protein components (mainly whey). The permeate (comprising complex HMO) from ultrafiltration was dried by spray drying. The composition of this dry fraction is about 50% lactose and about 30% complex oligosaccharides (HMO), the remainder being mainly peptides and ash. The HMO fraction is mainly fucosylated.

[0067] This method, or a similar method, can be used to obtain compositions comprising isolated complex oligosaccharides from any mammalian milk source. For example, complex oligosaccharides can be isolat...

Embodiment 2

[0068] Example 2. Preparation of a certain bifidobacterium-specific bovine colostrum oligosaccharide (BCO) composition and a composition supplemented with synthetically produced and purified fucosylated oligosaccharide (SPF)

[0069] A concentrated mixture of bovine colostrum oligosaccharides was obtained by the method as described by Christiansen et al. (2010) International Dairy Journal, 20: 630-636. Bovine colostrum (mainly derived from the first milking) is pasteurized by heating to 145°F for 30 minutes, cooled and centrifuged to skim it, separating it into cream (mainly fat) and skim milk (skim product). The skim milk is then ultrafiltered using a membrane with a 5-10 kDa cut-off to concentrate the protein components (mainly whey). The whey permeate was further microfiltered using a membrane with a 1 kDa cut-off to remove some lactose and concentrate the oligosaccharides in the retentate. The final composition was spray dried to produce a dry oligosaccharide fraction wit...

Embodiment 3

[0072] Example 3. Differences between BCO, BCOC, BMO and HMO components

[0073]BCOC fractions are commercially available as Immunel (Sterling Technology, USA) and were analyzed using the HPLC-MS method of Tao et al., (2008), J Dairy Science, 92:2991-3001 , and compared in Table 1 with oligosaccharide fractions derived from human milk (HMO), mature bovine milk (BMO) and bovine colostrum (BCO). The four compositions in Table 1 differ significantly from each other, and several features emerge immediately. BCOC contains several oligosaccharides not found in BMO, BCO or HMO, such as Hex(4) and Hex(3)HexNAc(1)NeuAc(1), and several oligosaccharides found in BCO and BMO are absent in BCOC , such as Hex(2)HexNAc(1)NeuAc(1), Hex(3)HexNAc(2), and Hex(4)NeuAc(2)NeuGc(1).

[0074]

[0075] Table 1. Key oligosaccharides distinguishing colostrum and BMO fractions as disclosed in Tao (2009), HMO fractions as revealed in Mills et al. (2012), and the bovine colostrum oligosaccharide conce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Some embodiments of the invention include a composition and method for treating dysbiosis in infants. The composition may include a mixture of activated bifidobacteria and a complex oligosaccharide wherein the complex oligosaccharide may be derived from a human or non-human source.

Description

field of invention [0001] The present invention relates generally to improving health, and more specifically to improving the human microbiome. Furthermore, embodiments of the present invention relate to activated bifidobacteria compositions, methods of producing activated bifidobacteria, and uses of the compositions to initiate and maintain a human gut microbiome enriched in bifidobacteria species to Promotes the development of gastrointestinal (GI) and immune function in human infants. technical background [0002] When a vaginally delivered human infant is breastfed, he or she will have a gastrointestinal microbiome unique in composition and diversity compared to any other time in their life. The GI microbiome is dominated by a single organism, which can be present in high concentrations (up to and exceeding 70% of the total microbiome). Today, however, the standard of obstetric care in general hospitals includes caesarean section (C procedure) and vaginal delivery, fol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/745A23C9/12A61K31/702A61P1/00
CPCA61K31/702A23V2002/00A23L29/30A23L33/135C12N1/04C12N1/20A61K35/745A61P1/00A23V2400/529A61K2300/00A23V2250/284A23C9/12
Inventor D·凯尔D·米尔斯S·弗里曼-夏基
Owner EVOLVE BIOSYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com